Changes in Patient-Reported Outcomes With Vedolizumab Therapy in Patients With Inflammatory Bowel Diseases (IBD)

• DOI: 10.14309/00000434-201710001-00624
• Publication Date: 2019-02-10T15:38:23Z
• Authors: Millie D. Long; Christopher Martin; Wenli Chen; Elizabeth Jaeger; Morris Barocas; Michelle Luo
• Keywords: Vedolizumab; Depression; Certolizumab pegol

Introduction: Patient-reported outcomes (PROs) are important measures to assess response in patients with IBD. Vedolizumab (VDZ) is a gut-selective monoclonal antibody that specifically binds α 4β7 integrin and blocks gut lymphocyte trafficking, approved for use moderate severe Crohn's disease (CD) ulcerative colitis (UC) who naïve or have previously been exposed tumor necrosis factor antagonists (anti-TNFs). Less known about the real-world experience of on VDZ changes PROs. Methods: We performed prospective cohort study investigating PROs within CCFA Partners cohort. All CD UC initiating from 2014 present had at least 6 months follow-up were included. stratified by biologic anti-TNF (BN) (BE) status. Outcomes included short inflammatory bowel diseases questionnaire (SIBDQ); PRO measurement information system (PROMIS) assessing anxiety, depression, fatigue, social satisfaction, sleep disturbance, pain interference; activity index (sCDAI) as measure clinical remission. Bivariate analyses describe differences BN BE status; analyzed. Results: was initiated 348 169 UC. The majority (54%) (65%) managed private practice settings (Table 1). A total 20 (6%) 32 (19%) BN. higher rates prior surgery (67%) than (37%, p=0.01); hospitalization (72%) (28%, p < 0.01). In overall IBD population, corticosteroid-free remission (CSFR) defined sCDAI 6-12 improved 20% 45% (difference 25%, p=0.03) vs improvement 24% 30% 6%, p=0.13). experienced greater improvements patients, significant satisfaction (p=0.03) 2). Multiple domains met minimally clinically patients.Table: No Caption availableTable: availableConclusion: predominantly used individuals this CSFR significantly after VDZ. Trends toward multiple additional also noted patients.